ELRASHED B. YASIN

Dr. ELRASHED B. YASIN

King Abdulaziz University, Jeddah, Makkah al Mukarramah, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
HAHeba Alkhatabi
Heba Alkhatabi
ELRASHED B. YASINELRASHED B. YASIN
ELRASHED B. YASIN
ZMZeenat Mirza
Zeenat Mirza
RARAED Alserihi
RAED Alserihi
RFRaed Felimban
Raed Felimban
ABAhmed Barefah
Ahmed Barefah
Background: Tumor protein 53 (TP53) is a tumor-suppressor gene and plays an essential role in apoptosis, cell cycle arrest, genomic stability, and DNA repair. Although it is the most often mutated gene in human cancer, it has respectively low frequency in hematological malignancy but is significantly linked with complex karyotype, poor prognosis, and chemotherapeutic response. Nevertheless, the prevalence and prognostic role of TP53 mutations in hematological malignancy in Saudi patients are not well reported. We, therefore, aim to assess the frequency of TP53 mutations in hematological malignancies in Saudi Arabia. Method: 20 different hematological malignancy samples were tested using fluorescence in situ hybridization (FISH) technique for TP53 deletion detection and next-generation sequencing (NGS) targeted panel was applied on 10 samples for mutations identification specifically TP53 mutation. Results: TP53 deletion was detected in 6 of 20 samples by FISH. Most of the 6 patients with TP53 deletion had acute lymphoblastic leukemia (ALL), and majority of them were child. NGS result revealed one heterozygous missense mutation in exon 5 of the TP53 gene (c. G9963A, p.H175R). Conclusion: To the best of our knowledge, the TP53 mutation is novel variant, and the first time we are reporting their association with myelodysplastic syndromic individual with complex karyotype. This study recommends further analysis of genomic mutations on bigger cohorts, utilizing high throughput technologies.

3 March 2023 in International Journal of Biomedicine
Verified
Journal Article
Closed access
RARaed Alserihi Raed Alserihi
Raed Alserihi Raed Alserihi
HAHameeda Ahmad Hameeda Ahmad
Hameeda Ahmad Hameeda Ahmad
HAHeba Alkhatabi Heba Alkhatabi
Heba Alkhatabi Heba Alkhatabi
TQTalal Qadah Talal Qadah
Talal Qadah Talal Qadah
SKShahad W. Kattan Shahad W. Kattan
Shahad W. Kattan Shahad W. Kattan
ABAhmad S. Barefah Ahmad S. Barefah
Ahmad S. Barefah Ahmad S. Barefah

9 December 2021 in Genes
Verified
Journal Article
Open access
PDF file
HAHeba Alkhatabi
Heba Alkhatabi
HSHaneen Bin saddeq
Haneen Bin saddeq
LALUAY ALYAMANI
LUAY ALYAMANI
TSThoraia Shinawi
Thoraia Shinawi
ELRASHED B. YASINELRASHED B. YASIN
ELRASHED B. YASIN
AAAdel Abuzenadah
Adel Abuzenadah
Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators.

6 November 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
MAMajed Naser Almashjary
Majed Naser Almashjary
ASAmmar M. Sahl
Ammar M. Sahl
MHMohannad S. Hazzazi
Mohannad S. Hazzazi
MAMohammad H. Alhashmi
Mohammad H. Alhashmi
WBWaleed M. Bawazir
Waleed M. Bawazir
ELRASHED B. YASINELRASHED B. YASIN
ELRASHED B. YASIN
Background: Chronic kidney disease (CKD) is a serious, long-term illness that damages kidneys and lowers glomerular filtration rate. CKD often causes anemia. Iron deficiency (ID) is common in these patients and worsens illness symptoms. Modern hematology analysers can measure reticulocyte mean cell hemoglobin (MCHr), which directly measures iron integration into erythrocyte hemoglobin. MCHr can improve iron deficiency detection in CKD patients, who have aberrant iron indicators due to chronic inflammation. This research aims to evaluate the effectiveness of MCHr as a marker for ID in patients with CKD. Method: To obtain data for this study, CBC, reticulocyte profile, and iron biomarkers were collected from King Khalid National Guard Hospital (Ref No. IRB/1861/23). Transferring saturation was calculated using (Serum iron/TIBC) × 100. GraphPad Prism 9 software was used to analyze the data, and Mann-Whitney, Spearman correlation, and ROC plots were used to determine MCHr's diagnostic performance. A p - value < 0.05 was considered significant. Result: The study compared 190 individuals undergoing hemodialysis (HD) with 165 healthy blood donors. The HD group showed lower levels of RBC, Hb, MCHr, serum iron, and total iron-binding capacity (TIBC). Despite anemia, the HD group had higher levels of ferritin and transferrin saturation (TSAT). MCHr demonstrated excellent diagnostic performance in identifying iron deficiency anemia (IDA), particularly in functional iron deficiency. When TSAT was < 20%, MCHr showed an AUC of 0.98, with 100% specificity and 72.41% sensitivity, significantly outperforming ferritin and TSAT in inflammatory settings. In the HD group with ferritin levels < 200 ng/mL, the MCHr cut-off value of < 31.20 pg had a sensitivity and specificity of 89.47% and an AUC of 0.89. When TSAT was < 20%, the MCHr cut-off value of < 23.95 pg had a sensitivity of 72.41%, specificity of 100%, and AUC of 0.98. Conclusions: Based on the findings, MCHr is more effective than ferritin and TSAT in detecting iron deficiency in hemodialysis patients. Future research should use MCH to investigate the impact of iron therapy with or without rHuEPO.

1 January 2024 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
HAHeba Alkhatabi
Heba Alkhatabi
WAWejdan Alqahtani
Wejdan Alqahtani
RAReem Alsolami
Reem Alsolami
AEAisha Elaimi
Aisha Elaimi
MHMohannad S. Hazzazi
Mohannad S. Hazzazi
ABAhmed Barefah
Ahmed Barefah
Purpose: Genetic mutations are major factors in the diagnosis and prognosis of leukemia, and it is difficult to assess these variants using single-gene analysis. Therefore, this study aimed to develop a fast and cost-effective method for genetic screening of myeloid malignancies using a customized next-generation sequencing (NGS) panel. Patients and Methods: A customized myeloid panel was designed and investigated in 15 acute myeloid leukemia patients. The panel included 11 genes that were most commonly mutated in myeloid malignancies. This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL. Results: Among the 15 patients, 14 actual pathogenic variants were identified in nine samples, and negative results were found in six samples. Positive findings were observed for JAK2, FLT3, SF3B1, and TET2. Interestingly, non-classical FLT3 mutations (c.1715A>C, c.2513delG, and c.2507dupT) were detected in patients who were negative for FLT3-ITD and TKD by routine molecular results. All identified variants were pathogenic, and the high coverage of the assay allowed us to predict variants at a low frequency (1%) with 1000x coverage. Conclusion: Utilizing a custom panel allowed us to identify variants that were not detected by routine tests or those that were not routinely investigated. Using the costuming panel will enable us to sequence all genes and discover new potential pathogenic variants that are not possible with other commercially available panels that focus only on hotspot regions. This study’s strength in utilizing NGS and implanting a customized panel to identify new pathogenic variants that might be common in our population and important in routine diagnosis for providing optimal healthcare for personalized medicine.

26 March 2025 in Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale
Verified
Journal Article
Open access
PDF file
MEMashaer Taha Edris
Mashaer Taha Edris
MMMaye Mohammad Merghani
Maye Mohammad Merghani
SGShaza Salih Gafar
Shaza Salih Gafar
AAAhmed Mohamed Asmeli
Ahmed Mohamed Asmeli
ELRASHED B. YASINELRASHED B. YASIN
ELRASHED B. YASIN
EAElshazali Widaa Ali
Elshazali Widaa Ali
Reduced Folate Carrier1 (RFC1) gene's metabolism is crucial for DNA synthesis, epigenetic mechanisms, and cellular methylation events. Nonetheless, RFC1 polymorphisms have drawn a lot of interest in current medical genetics studies. The objectives of the study were to ascertain the relationship between the risk of acute lymphoblastic leukemia in Sudanese patients and the genetic variant of RFC1 (G 80A). Using Real-Time Polymerase Chain Reaction (RT-PCR) method, 150 Acute Lymphoblastic Leukemia (ALL) patients and 150 healthy control volunteers had their DNA collected and examined for the case-control study. Version 25 of the Statistical Package for Social Science (SPSS) software was used to analyze the data. There was no discernible difference in the age or gender of the patients compared to the controls. According to Flow cytometry data, T-ALL accounts for 31 (21%) and B cell type accounts for 119 (79%). According to this study, there is a statistically significant correlation between the mean blast (p=0.050) and the mean total white blood cell count (p=0.000) in T-ALL cases. The genotype frequency of RFC1 (G80A) was found to be GG 39 (26.0%), GA 41 (27.3%), and 70 (46.7%) for AA in the cases, while GG 41 (27.3%), GA 28 (18.7%), and AA 81 (54.0%) in the control group. While the homozygous genotypes AA and GG were more common in the control group, the heterozygous genotype GA was more common in the patient group. On the other hand, the genotype distribution among the research groups was not statistically significant with odds ratio: 0.745 (0.473-1.174), p=0.192. In conclusion, RFC1 (G80A) polymorphism was not found to be associated with an increased risk of ALL, according to the findings of this investigation.